ReviewJournal of internal medicine2020
Hypervirulent Klebsiella pneumoniae - clinical and molecular perspectives.
Review in Journal of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 467 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
467 citing papers in PubMed, 3 syntheses or guidelines pooled it, 629 citations in OpenAlex.
- Hypervirulent Klebsiella pneumoniae Infections: A Systematic Review of Clinical, Microbiological, and Outcome Data From Reported Cases.MicrobiologyOpen · 2026Pooled it
- Antimicrobial resistance in hypermucoviscous and non-hypermucoviscousEmerging microbes & infections · 2025Pooled it
- Systematic review and meta-analysis on the carbapenem-resistant hypervirulent Klebsiella pneumoniae isolates.BMC pharmacology & toxicology · 2025Pooled it
- Wzi modulates immune evasion of hypervirulentVirulence · 2026Article
- Clinical and genomic profiling ofVirulence · 2026Article
- An overview of innate cellular immune responses against hypervirulentEmerging microbes & infections · 2026Review
- RecCVirulence · 2026Article
- Molecular characterisation of extended-Spectrum-Beta-lactamase-producingOne health (Amsterdam, Netherlands) · 2026Article
- RpoE-mediated virulence attenuation elicits protective immunity in hypervirulentEmerging microbes & infections · 2026Article
- Article
- Molecular Insights Into Hypervirulent Klebsiella pneumoniae: Identification and Correlation of Virulence Determinant.MicrobiologyOpen · 2026Article
- HypervirulentOpen forum infectious diseases · 2026Article
- Berberine inhibits the AcrB efflux pump and synergizes with meropenem against carbapenem-resistant hypervirulent Klebsiella pneumoniae: mechanistic insights and in vivo validation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Transcriptomic correlates of ceftazidime-avibactam collateral sensitivity in tigecycline-resistant NDM-producing enterobacter cloacae complex.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Malvidin-3-O-Rhamnoside Alleviates Klebsiella pneumoniae -Induced Acute Lung Injury by Regulating Macrophage-Mediated Inflammatory and Oxidative Pathways.Phytotherapy research : PTR · 2026Article
- Molecular determinants of antimicrobial resistance inMicrobiology spectrum · 2026Article
- A safe and anti-inflammatory plant-derived nanovesicle platform for targeted delivery in acute lung injury.Bioactive materials · 2026Article
- Emerging hypervirulent and extensively drug-resistant Klebsiella pneumoniae with potent biofilm formation as a new clinical challenge.Molecular biology reports · 2026Article
- Molecular Epidemiology ofMicroorganisms · 2026Article
- HypervirulentMicrobiology spectrum · 2026Article
407 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Hypervirulent Klebsiella pneumoniae (hvKp) has emerged as a concerning global pathogen. hvKp is more virulent than classical K. pneumoniae (cKp) and capable of causing community-acquired infections, often in healthy individuals. hvKp is carried in the gastrointestinal tract, which contributes to its spread in the community and healthcare settings. First recognized in Asia, hvKp arose as a leading cause of pyogenic liver abscesses. In the decades since, hvKp has spread globally and causes a variety of infections. In addition to liver abscesses, hvKp is distinct from cKp in its ability to metastasize to distant sites, including most commonly the eye, lung and central nervous system (CNS). hvKp has also been implicated in primary extrahepatic infections including bacteremia, pneumonia and soft tissue infections. The genetic determinants of hypervirulence are often found on large virulence plasmids as well as chromosomal mobile genetic elements which can be used as biomarkers to distinguish hvKp from cKp clinical isolates. These distinct virulence determinants of hvKp include up to four siderophore systems for iron acquisition, increased capsule production, K1 and K2 capsule types, and the colibactin toxin. Additionally, hvKp strains demonstrate hypermucoviscosity, a phenotypic description of hvKp in laboratory conditions that has become a distinguishing feature of many hypervirulent isolates. Alarmingly, multidrug-resistant hypervirulent strains have emerged, creating a new challenge in combating this already dangerous pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.